Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Vogenx
Private
Small Molecules for Metabolic Diseases
Company Info
Recent News
Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Vogenx joins IPO queue to fund phase 2-stage metabolic drug
Vogenx joins IPO queue to fund phase 2-stage metabolic drug
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer